

# James T Boyd

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11994612/publications.pdf>

Version: 2024-02-01

14  
papers

993  
citations

1039406

9  
h-index

1125271

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

1159  
citing authors

#	ARTICLE	IF	CITATIONS
1	A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies. <i>Clinical Parkinsonism &amp; Related Disorders</i> , 2020, 2, 25-34.	0.5	2
2	Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving a 2000mg Daily Dose of Levodopa. <i>Parkinson's Disease</i> , 2020, 2020, 1-11.	0.6	8
3	Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 928-936.	2.2	64
4	Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. <i>Journal of the Neurological Sciences</i> , 2017, 377, 137-143.	0.3	27
5	Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. <i>Journal of Parkinson's Disease</i> , 2017, 7, 117-127.	1.5	22
6	Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores. <i>Neurology</i> , 2017, 89, 1789-1794.	1.5	24
7	Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 40.	3.8	327
8	Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America. <i>Journal of the Neurological Sciences</i> , 2016, 366, 74-81.	0.3	6
9	Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. <i>Movement Disorders</i> , 2016, 31, 538-546.	2.2	91
10	Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. <i>Movement Disorders</i> , 2016, 31, 530-537.	2.2	88
11	Validation of an Ambulatory Capacity Measure in Parkinson Disease: A Construct Derived from the Unified Parkinson's Disease Rating Scale. <i>Journal of Parkinson's Disease</i> , 2015, 5, 67-73.	1.5	16
12	Parkinson's disease severity and use of dopaminergic medications. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 297-299.	1.1	6
13	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 543.	4.5	312
14	A novel presentation of an ocular geste antagoniste in cervical dystonia: a case report. <i>Tremor and Other Hyperkinetic Movements</i> , 2013, 3, .	1.1	0